VEGFA and hepatocellular carcinoma: Since the first tyrosine kinase inhibitor (TKI) sorafenib was proven to extend the survival in advanced HCC patients without compromising liver function in 2008 (5), multi-TKIs and vascular endothelial growth factor (VEGF) inhibitors have been integrated into standard systemic therapy for advanced HCC (6–9).